Longport, Inc. Announces Third Quarter 2008 Sales Activity

  
    
  
  
    
      Longport, Inc. (OTC PK:LPTI), a medical technology specialist in 
      high-frequency high resolution ultrasound imaging, today announced 
      information on orders received since the beginning of 2008.
    
    
      Sales activity by the end of the third quarter has totaled 33 EPISCAN 
      systems. All of the units have been sold into wound 
      prevention/assessment. Of the last ten sales, 3 systems were into 
      long-term care, and 7 systems were sold into acute hospitals.
    
    
      Sales into acute hospitals were a direct result of the new CMS Ruling, 
      which has now gone into effect. This CMS rule change states that 
      Medicaid and Medicare will no longer be held responsible for “reasonably 
      preventable” hospital-acquired pressure 
      ulcers. This rule is expected to benefit Longport’s 
      efforts in getting the EPISCAN I-200 ultrasound scanner accepted in 
      hospitals for use in pressure ulcer prevention. The EPISCAN is an 
      assessment tool which when used in conjunction with standard of care 
      visual skin assessment provides more reliable skin assessment and 
      improved documentation. The images the scanner generates can also help 
      facilities to initiate targeted preventative intervention earlier, 
      frequently avoiding pressure ulcers from developing.
    
    
      Paul Wilson, President of Longport, Inc. said “The 
      Company believes that the door into acute care is beginning to open for 
      the EPISCAN. We project acute care will become one of Longport’s 
      largest markets. In addition to the sales reported, the Company has 
      received inquiries from numerous acute hospitals each potentially 
      looking to purchase multiple systems.”
    
    
      Longport will also be exhibiting at the Clinical Symposium on Advances 
      in Skin and Wound Care, to be held October 26 - 30 in Las Vegas. This 
      symposium targets nurses, physicians, podiatrists, physical therapists, 
      dietitians, and others who manage skin and wound care patients across 
      the continuum of health care. Longport will be exhibiting at Booth 213.
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high resolution ultrasound imaging. After 
      several years and a multi-million dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.